玻璃体切割联合引流阀植入治疗伴玻璃体积血的新生血管性青光眼

Combined pars plana vitrectomy and glaucoma drainage valve implantation for neovascular glaucoma combined with vitreous hemorrhage

目的：评价玻璃体切割联合引流阀植入治疗伴玻璃体积血的新生血管性青光眼的效果。方法：对30例（30眼）伴玻璃体积血的新生血管性青光眼患者采用玻璃体切割联合Ahmed青光眼引流阀植入术治疗，术后随访10～20（平均12）mo。结果：术后眼压控制在6．0～21．0mmHg25眼（其中3例需加用一种降眼压药物），3例眼压〉21．0mmHg，2例长期低眼压，成功率83％。结论：玻璃体切割联合引流阀植入治疗伴玻璃体积血的新生血管性青光眼，术后成功率高，视力有所提高，并发症少。

AIM： To evaluate the effects of combined pars plana vitrectomy and glaucoma drainage implant for neovascular glaucoma combined with vitreous hemorrhage. METHODS： Thirty cases （30 eyes） with neovascular glaucoma accompanied by vitreous hemorrhage were performed combined pars plana vitrectomy and glaucoma drainage implant placement. The follow-up was 10-20 months, with a mean of 12 months. RESULTS： After operation, the lOPs of 25 eyes were controlled within the range of 6.0 - 21.0mmHg, in which the lOPs of 3 eyes were controlled with one additional antiglaucoma medication, The total success rate of lOP control was 83%. In the rest 5 eyes, the lOPs of 3 eyes were 〉 21mmHg, and other 2 eyes were 〈 6mmHg. CONCLUSION, Combined pars plana vitrectomy and glaucoma drainage implant placement for neovascular glaucoma combined with vitreous hemorrhage can reduce lOP, increase the operative success rate, preserve the visual function effectively and decrease postoperative complications,